Abstract
The pregnant patient with inflammatory bowel disease presents a number of challenges to the clinician. In addition to the management of the patient’s disease activity and the potential effects of disease on pregnancy, the clinician must also take into consideration any iatrogenic complications that may arise from the medical management of these conditions. Furthermore, should the patient elect to breastfeed her infant, the effect of drugs that may be passed through the breast milk must also be considered. This article focuses specifically on the issues of drug transfer to the fetus and to the breastfeeding infant. Meperidine is the sedative of choice for endoscopic procedures on pregnant patients, while benzodiazepines and propofol may be used with certain caveats. Amoxicillin/clavulanic acid and metronidazole are preferred if antibiotics are indicated for perianal Crohn’s disease or pouchitis. The majority of medications used in the treatment of luminal IBD in pregnancy are not associated with significant adverse effects, and thus can generally be used safely. Certain medications, such as aminosalicylates, corticosteroids, and cyclosporine, appear low risk, while others such as methotrexate and thalidomide are clearly contraindicated. The role of other immunomodulators and biologics remains to be clearly defined, although early experience with infliximab and similar agents appear to be low risk. Safety in breastfeeding varies considerably among medications. There are many issues to address when considering pharmaceutical intervention in the pregnant patient, and patients should be carefully counseled regarding potential teratogenicity or adverse outcomes of medication used during pregnancy and breastfeeding.
Keywords: Inflammatory bowel disease, crohn’s disease, ulcerative colitis, pregnancy, breastfeeding, fetus, post-partum
Current Drug Delivery
Title:Drug Transfer to the Fetus and to the Breastfeeding Infant: What Do We Know?
Volume: 9 Issue: 4
Author(s): Steven J. Bernick and Sunanda Kane
Affiliation:
Keywords: Inflammatory bowel disease, crohn’s disease, ulcerative colitis, pregnancy, breastfeeding, fetus, post-partum
Abstract: The pregnant patient with inflammatory bowel disease presents a number of challenges to the clinician. In addition to the management of the patient’s disease activity and the potential effects of disease on pregnancy, the clinician must also take into consideration any iatrogenic complications that may arise from the medical management of these conditions. Furthermore, should the patient elect to breastfeed her infant, the effect of drugs that may be passed through the breast milk must also be considered. This article focuses specifically on the issues of drug transfer to the fetus and to the breastfeeding infant. Meperidine is the sedative of choice for endoscopic procedures on pregnant patients, while benzodiazepines and propofol may be used with certain caveats. Amoxicillin/clavulanic acid and metronidazole are preferred if antibiotics are indicated for perianal Crohn’s disease or pouchitis. The majority of medications used in the treatment of luminal IBD in pregnancy are not associated with significant adverse effects, and thus can generally be used safely. Certain medications, such as aminosalicylates, corticosteroids, and cyclosporine, appear low risk, while others such as methotrexate and thalidomide are clearly contraindicated. The role of other immunomodulators and biologics remains to be clearly defined, although early experience with infliximab and similar agents appear to be low risk. Safety in breastfeeding varies considerably among medications. There are many issues to address when considering pharmaceutical intervention in the pregnant patient, and patients should be carefully counseled regarding potential teratogenicity or adverse outcomes of medication used during pregnancy and breastfeeding.
Export Options
About this article
Cite this article as:
J. Bernick Steven and Kane Sunanda, Drug Transfer to the Fetus and to the Breastfeeding Infant: What Do We Know?, Current Drug Delivery 2012; 9 (4) . https://dx.doi.org/10.2174/156720112801323116
DOI https://dx.doi.org/10.2174/156720112801323116 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Nanoemulsions in cancer therapy
Solid tumors are characterized by leaky vascular structure, defective angiogenesis and high interstitial fluid load, providing opportunities for nanoparticles to preferentially exudate and be retained in tumors. This phenomenon is commonly referred to as the enhanced permeability and retention (EPR) effect, which is considered to be an important reason why ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Discovery of VLA-4 Antagonists
Current Topics in Medicinal Chemistry Bariatric Surgery and Rheumatic Diseases: A Literature Review
Reviews on Recent Clinical Trials Therapeutic and Diagnostic Agents based on Bioactive Endogenous and Exogenous Coordination Compounds
Current Medicinal Chemistry Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review
Current Pharmaceutical Design Retrospective Review of Chromane Analogues as Anti-protozoal Leads: A Decade's Worth of Evolution
Current Topics in Medicinal Chemistry Pleural Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy Cyclophilins in Atherosclerosis: A New Therapeutic Target?
Current Pharmaceutical Design Recent Developments of Useful MALDI Matrices for the Mass Spectrometric Characterization of Apolar Compounds
Current Organic Chemistry A Study on the Biological Activity of 2-thioxo-imidazolidin-4-ones
Letters in Drug Design & Discovery Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology Synovial Chondromatosis of the Shoulder in Rheumatoid Arthritis: A Case Report and Brief Review of the Literature
Current Rheumatology Reviews Hypusine Modification of the Ribosome-binding Protein eIF5A, a Target for New Anti-Inflammatory Drugs: Understanding the Action of the Inhibitor GC7 on a Murine Macrophage Cell Line
Current Pharmaceutical Design Emerging Trends in Endometriosis Treatment - Review
Current Women`s Health Reviews Arthritis of the Hip Caused by Arteriovenous Malformations: A Case Report
Current Medical Imaging Microneedle-Based Drug Delivery Systems for Transdermal Route
Current Drug Targets SUBJECT INDEX TO VOLUME 1
Current Drug Targets Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress
Current Medicinal Chemistry - Anti-Cancer Agents Peroxynitrite-Mediated Structural Changes in Histone H2A: Biochemical and Biophysical Analysis
Protein & Peptide Letters